SuperworthNeuphoria Therapeutics NEUP
- Market cap
- $18.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Neuphoria Therapeutics' trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n/a | n/a | n/a | n/a | n/a | $662.7K | $15M | n/a | n/a | n/a | n/a | n/a | |
| R&D | $3.1M | $2M | $1.2M | $3.1M | $1.9M−38% | $1.7M−15% | $1.6M+35% | n/a | $3.8M+99% | $697.7K−60% | −$518.2K | n/a |
| SG&A | $2.4M | $2.5M | $1.2M | $2.4M | $1.7M−30% | $2.6M+4% | $1.4M+18% | n/a | $1.9M+12% | $2.1M−19% | $1.7M+20% | n/a |
| −$5.5M | −$4.6M | −$2.4M | −$5.5M | −$3.6M−35% | −$3.7M−19% | $12M | n/a | −$5.7M+58% | −$4.1M+10% | −$1.2M | n/a | |
| Pre-tax income | −$5.5M | −$4.6M | −$2.8M | −$2.7M | −$937K−83% | −$1.9M−58% | $11.2M | n/a | −$9.9M+961% | $1.8M | −$539.9K | n/a |
| −$34.8K | −$34.8K | $16.4K | −$34.1K | −$132.2K+280% | $11.6K | −$81.2K | n/a | −$34.8K−74% | −$34.8K | −$34.8K−57% | n/a | |
| Net income | −$5.5M | −$4.6M | −$2.8M | −$2.7M | −$804.8K−85% | −$1.9M−57% | $11.3M | −$8.9M+231% | −$9.9M+1131% | $1.9M | −$505.1K | −$4.9M−45% |
| $0.00 | −$5.31 | −$2.83 | −$1.24 | −$0.62 | −$1.79−66% | $6.55 | −$4.67+277% | −$4.41+611% | −$0.77−57% | −$0.09 | −$0.91−81% | |
| 124.7K | 857.3K | 981K | 2.2M | 1.3M+943% | 1.6M+84% | 1.7M+75% | 1.9M−12% | 2.2M+73% | 4.5M+188% | 5.4M+215% | 5.4M+184% |
EPS, diluted: 3 periods, Q4 FY24 to Q4 FY26: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average over 366 days less the 9-month over 275, the two on one basis (x2.16). Q4 FY25 and Q4 FY26: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Neuphoria Therapeutics' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NEUPNeuphoria Therapeutics | $18.6M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Neuphoria Therapeutics
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .